l

Colts QB Philip Rivers to coach at Alabama high school once NFL career ends

Indianapolis Colts quarterback Philip Rivers will become the head football coach at St. Michael Catholic High School, the school announced Friday.




l

'Shoeless' Joe Jackson baseball card from 1910 sells for $492K at auction

A "Shoeless" Joe Jackson baseball card from 1910 sold at auction for $492,000 this week.




l

Drug may curb dangerous urges in pedophiles, study says

A testosterone-lowering drug can reduce male pedophiles' risk of sexually abusing children, according to a new Swedish study.




l

FDA approves first at-home saliva test for COVID-19

The first COVID-19 test using saliva samples that patients collect at home has been approved by the U.S. Food and Drug Administration.




l

Planet already seeing temps beyond human tolerability

Researchers have predicted that if climate change goes unabated, the planet will experience intolerable heat in several decades. But a new study has found that in certain global hot spots, it's already happening.




l

Metabolic Effects of Dietary Sucrose in Type II Diabetic Subjects

John P Bantle
Sep 1, 1993; 16:1301-1305
Short Report




l

Evidence-Informed Clinical Practice Recommendations for Treatment of Type 1 Diabetes Complicated by Problematic Hypoglycemia

Pratik Choudhary
Jun 1, 2015; 38:1016-1029
Type 1 Diabetes at a Crossroads




l

Endothelial Dysfunction in Diabetes: The role of reparatory mechanisms

Angelo Avogaro
May 1, 2011; 34:S285-S290
Hypertension




l

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes

Jens J. Holst
May 1, 2011; 34:S251-S257
Diabetes Treatments




l

Lipid and Inflammatory Cardiovascular Risk Worsens Over 3 Years in Youth With Type 2 Diabetes: The TODAY clinical trial

TODAY Study Group
Jun 1, 2013; 36:1758-1764
TODAY Study




l

The Reality of Type 2 Diabetes Prevention

Richard Kahn
Apr 1, 2014; 37:943-949
Current Concepts of Type 2 Diabetes Prevention




l

Kidney Disease and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study

Ian H. de Boer
Jan 1, 2014; 37:24-30
DCCT/EDIC 30th Anniversary Summary Findings




l

Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013

Kasia J. Lipska
Apr 1, 2017; 40:468-475
Emerging Science and Concepts for Management of Diabetes and Aging




l

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

Hannele Yki-Järvinen
Dec 1, 2014; 37:3235-3243
Emerging Technologies and Therapeutics




l

Day and Night Home Closed-Loop Insulin Delivery in Adults With Type 1 Diabetes: Three-Center Randomized Crossover Study

Lalantha Leelarathna
Jul 1, 2014; 37:1931-1937
Emerging Technologies and Therapeutics




l

Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON

Muh Geot Wong
May 1, 2016; 39:694-700
Cardiovascular Disease and Diabetes




l

Influence of Dietary Protein Intake on Whole-Body Protein Turnover in Humans

Peter J Garlick
Dec 1, 1991; 14:1189-1198
Diet and Diabetes




l

Feasibility of Outpatient Fully Integrated Closed-Loop Control: First studies of wearable artificial pancreas

Boris P. Kovatchev
Jul 1, 2013; 36:1851-1858
Diabetes Care Symposium




l

Psychosocial Problems and Interventions in Diabetes: A review of the literature

Richard R Rubin
Nov 1, 1992; 15:1640-1657
Behavioral Diabetes Series




l

Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia

Bernhard J. Hering
Jul 1, 2016; 39:1230-1240
Emerging Technologies and Therapeutics




l

The Fallacy of Average: How Using HbA1c Alone to Assess Glycemic Control Can Be Misleading

Roy W. Beck
Aug 1, 2017; 40:994-999
Perspectives in Care




l

Overnight Closed-Loop Insulin Delivery in Young People With Type 1 Diabetes: A Free-Living, Randomized Clinical Trial

Roman Hovorka
May 1, 2014; 37:1204-1211
Advances in Artificial Pancreas Development




l

Framingham, SCORE, and DECODE Risk Equations Do Not Provide Reliable Cardiovascular Risk Estimates in Type 2 Diabetes

Ruth L. Coleman
May 1, 2007; 30:1292-1293
BR Cardiovascular and Metabolic Risk




l

National Standards for Diabetes Self-Management Education and Support

Linda Haas
Jan 1, 2014; 37:S144-S153
National Standards




l

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

Ralph A. DeFronzo
Oct 1, 2013; 36:3169-3176
Emerging Technologies and Therapeutics




l

Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

Robert R. Henry
Mar 1, 2015; 38:412-419
Evolving Tactics With Inhibition of Sodium-Glucose Cotransporters




l

Vitamin E Reduction of Protein Glycosylation in Diabetes: New Prospect for Prevention of Diabetic Complications?

Antonio Ceriello
Jan 1, 1991; 14:68-72
Short Report




l

Early Signs of Cardiovascular Disease in Youth With Obesity and Type 2 Diabetes

Neslihan Gungor
May 1, 2005; 28:1219-1221
BR Pathophysiology/Complications




l

Pathways to Quality Inpatient Management of Hyperglycemia and Diabetes: A Call to Action

Boris Draznin
Jul 1, 2013; 36:1807-1814
Perspectives in Care




l

Prevalence of Hyper- and Hypoglycemia Among Inpatients With Diabetes: A national survey of 44 U.S. hospitals

Deborah J. Wexler
Feb 1, 2007; 30:367-369
BR Epidemiology/Health Services/Psychosocial Research




l

In-Hospital Prognosis of Ppatients With Fasting Hyperglycemia After First Myocardial Infarction

John J O'Sullivan
Aug 1, 1991; 14:758-760
Short Report




l

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Hans-Ulrich Häring
Jun 1, 2014; 37:1650-1659
Emerging Technologies and Therapeutics




l

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

Tadej Battelino
Aug 1, 2019; 42:1593-1603
International Consensus Report




l

Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes

Michaela Diamant
Oct 1, 2014; 37:2763-2773
Emerging Technologies and Therapeutics




l

Serum 25-Hydroxyvitamin D3 Concentrations and Prevalence of Cardiovascular Disease Among Type 2 Diabetic Patients

Massimo Cigolini
Mar 1, 2006; 29:722-724
BR Cardiovascular and Metabolic Risk




l

Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors' Expert Forum

Itamar Raz
Jun 1, 2013; 36:1779-1788
Diabetes Care Expert Forum




l

Consensus Development Conference on Insulin Resistance: 5-6 November 1997

American Diabetes Association
Feb 1, 1998; 21:310-314
Consensus Development Conference Report




l

Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes

Robert R. Henry
Dec 1, 2015; 38:2258-2265
Special Article Collection: Insulin




l

Update on Cardiovascular Outcomes at 30 Years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study

John M. Lachin
Jan 1, 2014; 37:39-43
DCCT/EDIC 30th Anniversary Summary Findings




l

High Prevalence of Hepatitis C Virus Infection in Diabetic Patients

Rafael Simó
Sep 1, 1996; 19:998-1000
Short Report




l

Manufactured Shoes in the Prevention of Diabetic Foot Ulcers

Luigi Uccioli
Oct 1, 1995; 18:1376-1378
Short Report




l

Breaking Up Prolonged Sitting With Standing or Walking Attenuates the Postprandial Metabolic Response in Postmenopausal Women: A Randomized Acute Study

Joseph Henson
Jan 1, 2016; 39:130-138
IDF-ADA Translational Symposium




l

Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?

Samy Suissa
Jan 1, 2018; 41:6-10
Perspectives in Care




l

A Low-Glycemic Load Diet Facilitates Greater Weight Loss in Overweight Adults With High Insulin Secretion but Not in Overweight Adults With Low Insulin Secretion in the CALERIE Trial

Anastassios G. Pittas
Dec 1, 2005; 28:2939-2941
BR Clinical Care/Education/Nutrition




l

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

Matthew C. Riddle
Oct 1, 2014; 37:2755-2762
Emerging Technologies and Therapeutics




l

Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes: The TODAY clinical trial

TODAY Study Group
Jun 1, 2013; 36:1735-1741
TODAY Study




l

A Mathematical Model for the Determination of Total Area Under Glucose Tolerance and Other Metabolic Curves

Mary M Tai
Feb 1, 1994; 17:152-154
Short Report




l

Increased Carotid Intima-Media Thickness and Stiffness in Obese Children

Arcangelo Iannuzzi
Oct 1, 2004; 27:2506-2508
Brief Reports




l

Acute Effects of Insulin in the Control of VLDL Production in Humans: Implications for the insulin-resistant state

Gary F Lewis
Apr 1, 1996; 19:390-393
Symposium On Insulin Resistance




l

Prevalence of Diabetes in Mexican Americans, Cubans, and Puerto Ricans From the Hispanic Health and Nutrition Examination Survey, 1982-1984

Katherine M Flegal
Jul 1, 1991; 14:628-638
Supplement 3: Diabetes in Hispanic Americans